SGLT inhibitors, such as dapagliflozin and canagliflozin, are a class of medications used to treat type 2 diabetes. These drugs inhibit the function of SGLT2 in the kidneys, reducing glucose reabsorption and promoting glucose excretion in the urine. This mechanism helps lower blood glucose levels and has been shown to have additional benefits, such as weight loss and reduced cardiovascular risk.
